The women participated as outpatients at the New York State Psychiatric Institute. Data were collected on a range of subject-rated, observer-rated and performance measures before drug administration and over a 4 h time course following drug administration. After participants had passed all study entry criteria, they had a training session and a practice session; placebo capsules and a placebo beverage were administered during the practice session. The purpose of these sessions was to 1) familiarize participants with the routines to be followed, 2) provide training on the performance tasks, and 3) reduce expectancies related to capsule and beverage administration. Data from these sessions were not analyzed. Participants then started the double-blind testing phase: sessions were scheduled during the late luteal phase (1–5 days before the onset of menstruation) and during the midfollicular phase (6–10 days after the onset of menstruation). During each menstrual cycle phase participants received alcohol (0.0, 0.25, and 0.75 g/kg) on separate days. The dose order was randomized within each group and across the FHP and FHN groups.
